The rolvedon market research report is one of a series of new reports that provides rolvedon market statistics, including the rolvedon industry global market size, regional shares, competitors with the rolvedon market share, detailed rolvedon market segments, market trends, and opportunities, and any further data you may need to thrive in the rolvedon industry. This rolvedon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing adoption of biosimilars, increasing number of approvals, rising number of chemotherapy recipients, rising awareness of neutropenia management, and demand for effective prophylactic treatments. Major trends in the forecast period include technological breakthroughs, innovations in filgrastim usage, advancements in healthcare infrastructure, innovative treatment modalities, and innovations to introduce novel therapies.
The growing prevalence of cancer is expected to drive the expansion of the rolvedon market in the future. Cancer is a collection of diseases characterized by uncontrolled cell growth and spread, which can lead to tumor formation, tissue invasion, and metastasis. The rise in cancer cases is largely attributed to factors such as aging populations, lifestyle choices, environmental exposures, genetic factors, and better diagnostic methods. Rolvedon assists cancer patients by stimulating the production of white blood cells, particularly increasing neutrophil counts, which helps reduce the risk of infection during chemotherapy and strengthens the immune system. For example, according to the Australian Institute of Health and Welfare, in 2022, cancer diagnoses in Australia increased from 156,781 in 2021 to 160,570, showing a rise of 3,789 cases in just one year. Therefore, the growing incidence of cancer is contributing to the growth of the rolvedon market.
A key development in the rolvedon market is the emergence of biologic medications, which are revolutionizing treatment approaches by offering targeted therapies with greater effectiveness and fewer side effects. Biologic drugs are derived from living organisms or their cells, including proteins and antibodies, and are used to treat various conditions, including cancer and autoimmune diseases. In September 2022, Spectrum Pharmaceuticals, a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Rolvedon (eflapegrastim-xnst). This novel treatment is designed to reduce the incidence of infections, particularly febrile neutropenia, in adult patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. The approval of Rolvedon marked a major milestone for Spectrum, positioning the company to tap into a $2 billion market opportunity.
In April 2023, Assertio Holdings Inc., a U.S.-based pharmaceutical company, acquired Spectrum Pharmaceuticals, Inc. in an effort to strengthen its oncology portfolio. This acquisition is intended to accelerate Assertio’s revenue growth and improve market access for its products through enhanced integration and operational efficiencies. Spectrum Pharmaceuticals is the developer of Rolvedon, a drug specifically designed for chemotherapy-induced neutropenia.
The key company operating in the rolvedon market is Hanmi Pharm Co Ltd.
North America was the largest region in the rolvedon market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rovedon report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rovedon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rolvedon is a medication used to reduce the risk of infection in cancer patients undergoing chemotherapy. It is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells, especially neutrophils, which play a crucial role in fighting infections.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main clinical indications for Rolvedon are based on its primary indication, the patient population, and the treatment context. The primary indication refers to the specific medical condition or disease that the drug is approved and marketed to treat. Rolvedon is distributed through various channels, including hospital pharmacies, retail pharmacies, and online platforms, and is used by a range of end users, such as hospitals, clinics, specialty centers, homecare settings, and research and academic institutions.
The rovedon market consists of sales of syringes and injection devices, biologic drugs for neutropenia, diagnostic and monitoring equipment, oncology care kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing adoption of biosimilars, increasing number of approvals, rising number of chemotherapy recipients, rising awareness of neutropenia management, and demand for effective prophylactic treatments. Major trends in the forecast period include technological breakthroughs, innovations in filgrastim usage, advancements in healthcare infrastructure, innovative treatment modalities, and innovations to introduce novel therapies.
The growing prevalence of cancer is expected to drive the expansion of the rolvedon market in the future. Cancer is a collection of diseases characterized by uncontrolled cell growth and spread, which can lead to tumor formation, tissue invasion, and metastasis. The rise in cancer cases is largely attributed to factors such as aging populations, lifestyle choices, environmental exposures, genetic factors, and better diagnostic methods. Rolvedon assists cancer patients by stimulating the production of white blood cells, particularly increasing neutrophil counts, which helps reduce the risk of infection during chemotherapy and strengthens the immune system. For example, according to the Australian Institute of Health and Welfare, in 2022, cancer diagnoses in Australia increased from 156,781 in 2021 to 160,570, showing a rise of 3,789 cases in just one year. Therefore, the growing incidence of cancer is contributing to the growth of the rolvedon market.
A key development in the rolvedon market is the emergence of biologic medications, which are revolutionizing treatment approaches by offering targeted therapies with greater effectiveness and fewer side effects. Biologic drugs are derived from living organisms or their cells, including proteins and antibodies, and are used to treat various conditions, including cancer and autoimmune diseases. In September 2022, Spectrum Pharmaceuticals, a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Rolvedon (eflapegrastim-xnst). This novel treatment is designed to reduce the incidence of infections, particularly febrile neutropenia, in adult patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. The approval of Rolvedon marked a major milestone for Spectrum, positioning the company to tap into a $2 billion market opportunity.
In April 2023, Assertio Holdings Inc., a U.S.-based pharmaceutical company, acquired Spectrum Pharmaceuticals, Inc. in an effort to strengthen its oncology portfolio. This acquisition is intended to accelerate Assertio’s revenue growth and improve market access for its products through enhanced integration and operational efficiencies. Spectrum Pharmaceuticals is the developer of Rolvedon, a drug specifically designed for chemotherapy-induced neutropenia.
The key company operating in the rolvedon market is Hanmi Pharm Co Ltd.
North America was the largest region in the rolvedon market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rovedon report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rovedon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rolvedon is a medication used to reduce the risk of infection in cancer patients undergoing chemotherapy. It is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells, especially neutrophils, which play a crucial role in fighting infections.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main clinical indications for Rolvedon are based on its primary indication, the patient population, and the treatment context. The primary indication refers to the specific medical condition or disease that the drug is approved and marketed to treat. Rolvedon is distributed through various channels, including hospital pharmacies, retail pharmacies, and online platforms, and is used by a range of end users, such as hospitals, clinics, specialty centers, homecare settings, and research and academic institutions.
The rovedon market consists of sales of syringes and injection devices, biologic drugs for neutropenia, diagnostic and monitoring equipment, oncology care kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Rolvedon Market Characteristics4. Rolvedon Market Trends And Strategies5. Rolvedon Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Rolvedon Pricing Analysis & Forecasts30. Global Rolvedon Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Rolvedon Market32. Recent Developments In The Rolvedon Market
3. Rolvedon Market Biologic Drug Characteristics
6. Global Rolvedon Growth Analysis And Strategic Analysis Framework
8. Rolvedon Market Segmentation
9. Global Rolvedon Epidemiology Of Clinical Indications
10. Rolvedon Market Regional And Country Analysis
11. Asia-Pacific Rolvedon Market
12. China Rolvedon Market
13. India Rolvedon Market
14. Japan Rolvedon Market
15. Australia Rolvedon Market
16. South Korea Rolvedon Market
17. Western Europe Rolvedon Market
18. UK Rolvedon Market
19. Germany Rolvedon Market
20. France Rolvedon Market
21. Eastern Europe Rolvedon Market
22. North America Rolvedon Market
23. USA Rolvedon Market
24. Canada Rolvedon Market
25. South America Rolvedon Market
26. Middle East Rolvedon Market
27. Africa Rolvedon Market
28. Rolvedon Market Competitive Landscape And Company Profiles
29. Global Rolvedon Market Pipeline Analysis
33. Rolvedon Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Rolvedon Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rolvedon market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rolvedon ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rolvedon market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Primary Indication; Patient Population; Treatment Context2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Hospitals And Clinics; Specialty Centers; Homecare Settings; Research And Academic Institutions
Key Companies Profiled: Hanmi Pharm Co Ltd
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Hanmi Pharm Co Ltd
